UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

Status Withdrawn

Clinical Trial Summary

This is a single arm, open-label, single-center prospective study to determinethe safety and efficacy of CTA30X UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B Hematologic Malignancies

Clinical Trial Description

The main aim of the study is to determine the safety and efficacy of CTA30X UCAR-T in R/R B Hematologic Malignancies. CTA30X UCAR-T is an allogeneic chimeric antigenreceptor T-cell (CAR-T) therapy that targets CD19 and B-cell Hematologic Malignancies. The study will include 72 subjects to receive CTA30X UCAR-T singleinfusion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05015972
Study type	Interventional
Source	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Contact
Status	Withdrawn
Phase	Early Phase 1
Start date	August 20, 2021
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Withdrawn	`NCT05929716` - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma	Phase 2
Active, not recruiting	`NCT05024045` - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers	Phase 1
Recruiting	`NCT05016947` - Venetoclax Plus Inotuzumab for B-ALL	Phase 1
Completed	`NCT02900716` - Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas	Phase 1
Completed	`NCT03068416` - CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy	Phase 2
Not yet recruiting	`NCT05014100` - Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma	Phase 2
Recruiting	`NCT05934838` - A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas	Phase 1
Terminated	`NCT04023071` - FT516 in Subjects With Advanced Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT04148430` - A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy	Phase 2
Completed	`NCT02933320` - BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia	Phase 1/Phase 2
Active, not recruiting	`NCT03133221` - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Phase 2
Completed	`NCT02741388` - A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP	Phase 1
Terminated	`NCT02266147` - Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma	Phase 1/Phase 2
Completed	`NCT02300402` - Detection and Characterization of Residual Masses in Lymphomas
Terminated	`NCT00906841` - Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma	Phase 2
Completed	`NCT00338494` - Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma	Phase 1
Recruiting	`NCT05487651` - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies	Phase 1
Withdrawn	`NCT05570188` - Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT03281551` - Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma	Phase 1